Holen Sie sich die Stockscreener-App
0.764
12.35%
0.084
Handel nachbörslich:
.75
-0.014
-1.83%
Schlusskurs vom Vortag:
$0.68
Offen:
$0.69
24-Stunden-Volumen:
970.05K
Relative Volume:
0.60
Marktkapitalisierung:
$70.91M
Einnahmen:
$153.73M
Nettoeinkommen (Verlust:
$-106.79M
KGV:
-0.4292
EPS:
-1.78
Netto-Cashflow:
$-115.93M
1W Leistung:
-5.13%
1M Leistung:
-15.56%
6M Leistung:
-60.41%
1J Leistung:
-74.19%
1-Tages-Spanne:
$0.6875
$0.7916
1-Wochen-Bereich:
$0.6736
$0.84
52-Wochen-Spanne:
$0.5231
$5.17
Sutro Biopharma Inc Stock (STRO) Company Profile
Firmenname
Sutro Biopharma Inc
Sektor
Branche
Telefon
650-392-8412
Adresse
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Vergleichen Sie STRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
0.764 | 70.91M | 153.73M | -106.79M | -115.93M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-03-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-03-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-03-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-05-08 | Eingeleitet | BofA Securities | Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-06 | Eingeleitet | Oppenheimer | Outperform |
| 2023-03-21 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-06-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-09-02 | Eingeleitet | Jefferies | Buy |
| 2020-07-16 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-10-07 | Eingeleitet | BTIG Research | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2019-04-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-10-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-10-22 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Sutro Biopharma Inc Aktie (STRO) Neueste Nachrichten
Sutro Biopharma (NASDAQ:STRO) Upgraded to Overweight at Piper Sandler - Defense World
Sutro Biopharma (STRO) Receives Upgrade to Overweight by Piper S - GuruFocus
Piper Sandler Upgrades Sutro Biopharma to Overweight From Neutral, $2 Price Target - MarketScreener
Sutro Biopharma (STRO) Receives Upgrade with Promising Drug Prospects | STRO Stock News - GuruFocus
Piper Sandler upgrades Sutro Biopharma stock rating on pipeline progress By Investing.com - Investing.com Canada
Bank of America Corp DE Sells 22,894 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of “Hold” by Analysts - Defense World
Piper Sandler Upgrades Sutro Biopharma (STRO) to Overweight | ST - GuruFocus
Sutro Biopharma, Inc. (NASDAQ:STRO) Stock Position Decreased by Two Sigma Investments LP - Defense World
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Millennium Management LLC - Defense World
ProShare Advisors LLC Boosts Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Nuveen Asset Management LLC Acquires 124,154 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma names Greg Chow as new CFO - Investing.com
Sutro Biopharma (STRO) Appoints New CFO Greg Chow | STRO Stock N - GuruFocus
Sutro Biopharma names Greg Chow as new CFO By Investing.com - Investing.com Canada
Sutro Biopharma Appoints Greg Chow as Chief Financial Officer - The Manila Times
Sutro Biopharma Strengthens ADC Leadership: New CFO Brings $225M Capital Raising Track Record - Stock Titan
Two Sigma Advisers LP Has $1.01 Million Stock Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Northern Trust Corp Buys 14,492 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
BNP Paribas Financial Markets Buys 68,234 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma’s SWOT analysis: stock shifts focus amid pipeline changes By Investing.com - Investing.com Nigeria
Sutro Biopharma’s SWOT analysis: stock shifts focus amid pipeline changes - Investing.com
Sutro Biopharma unveils best-in-class anti-tissue factor ADC - BioWorld MedTech
Sutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of “Hold” by Brokerages - Defense World
Sutro Biopharma (NASDAQ:STRO) Price Target Cut to $0.80 by Analysts at Bank of America - Defense World
Sutro Biopharma (STRO): Analyst Lowers Price Target by 20% | STR - GuruFocus
Bank of America Adjusts Sutro Biopharma (STRO) Price Target | ST - GuruFocus
Dimensional Fund Advisors LP Buys 156,139 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma Reports Q1 2025 Earnings and Restructuring - TipRanks
Transcript : Sutro Biopharma, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 04 - marketscreener.com
Sutro Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Barclays PLC - Defense World
Sutro Biopharma Inc Reports Q1 2025 Revenue of $17.4M, Exceeding Estimates; EPS at -$0.91, Missing Projections - GuruFocus
Sutro Biopharma First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates - NewsBreak: Local News & Alerts
Sutro Biopharma earnings missed by $0.06, revenue topped estimates - Investing.com Canada
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights - The Manila Times
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights | STRO Stock News - GuruFocus
Sutro Biopharma, Inc. Advances ADC Pipeline Focus with Promising Preclinical Results and Strategic Reprioritization - Nasdaq
Financial Metrics Check: Sutro Biopharma Inc (STRO)’s Ratios for Trailing Twelve Months - DWinneX
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Bought by Invesco Ltd. - Defense World
Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Globe and Mail
Sutro Biopharma (NASDAQ:STRO) Earns Neutral Rating from HC Wainwright - The AM Reporter
Sutro Biopharma to Participate in Upcoming Investor Conferences - The Manila Times
Leading ADC Developer Sutro Biopharma to Present at Citizens and BofA Healthcare Conferences in May - Stock Titan
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty - Benzinga
Sutro Biopharma (NASDAQ:STRO) Earns “Neutral” Rating from HC Wainwright - Defense World
Taking the lead: Sutro Biopharma Inc (STRO) - Sete News
Finanzdaten der Sutro Biopharma Inc-Aktie (STRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sutro Biopharma Inc-Aktie (STRO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
May 01 '25 |
Option Exercise |
0.00 |
37,849 |
0 |
133,282 |
| Srinivasan Venkatesh | CHIEF TECH OP OFFICER |
May 01 '25 |
Option Exercise |
0.00 |
2,500 |
0 |
54,580 |
| Borgman Anne Elizabeth | CHIEF MEDICAL OFFICER |
May 01 '25 |
Option Exercise |
0.00 |
69,063 |
0 |
122,161 |
| Srinivasan Venkatesh | CHIEF TECH OP OFFICER |
Apr 11 '25 |
Option Exercise |
0.00 |
21,250 |
0 |
59,683 |
| NEWELL WILLIAM J | CEO |
Mar 05 '25 |
Option Exercise |
0.00 |
18,750 |
0 |
299,239 |
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
Mar 05 '25 |
Option Exercise |
0.00 |
8,750 |
0 |
99,027 |
| ALBINI EDWARD C | CFO AND SECRETARY |
Mar 05 '25 |
Option Exercise |
0.00 |
8,750 |
0 |
135,675 |
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
Mar 04 '25 |
Option Exercise |
0.00 |
9,125 |
0 |
94,025 |
| NEWELL WILLIAM J | CEO |
Mar 04 '25 |
Option Exercise |
0.00 |
31,125 |
0 |
291,625 |
| Chung Jane | PRESIDENT AND COO |
Mar 04 '25 |
Option Exercise |
0.00 |
7,875 |
0 |
100,642 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):